CN1277634A

CN1277634A - New tissue-specific calpaines, their production and their use

Info

Publication number: CN1277634A
Application number: CN98810562A
Authority: CN
Inventors: T·贝姆; N·T·德尔
Original assignee: BASF SE
Current assignee: BASF SE
Priority date: 1997-08-26
Filing date: 1998-08-19
Publication date: 2000-12-20
Also published as: WO1999010480A2; CA2301815A1; DE19737105A1; ZA987660B; IL134361A0; HUP0004027A2; WO1999010480A3; AU9263598A; NO20000961D0; KR20010023282A; BR9811365A; EP1009811A2; NO20000961L; JP2001513992A

Abstract

The invention relates to new tissue-specific calpaines and their production. The invention also relates to a method for screening for new calpaine inhibitors and their use.

Description

Novel tissue-specific calpaines enzyme, Preparation Method And The Use

The present invention relates to novel tissue-specific calpaines enzyme and its preparation method.

In addition, the present invention relates to screen method and its purposes of novel calpain inhibitor.

Calpain is the interior non-lysosomal enzyme of cell that belongs to the L-Cysteine HCL Anhydrous group.They in eukaryotic cell with Ca ²⁺The signal transduction that relies on is relevant, and promptly they are to rely on Ca ²⁺The mode of concentration is controlled cell function.Calpain extensively exists in animal tissues and as the cell of people, chicken, rabbit and rat.Calpain is also found in the low animal of waiting such as drosophila melanogaster, Schistosoma or Caenorhabditis elegans.Up to now, in yeast, fungi or bacterium, do not detect calpain.

Up to now, known these three kinds of extensively having calpain are mainly with the I type, and rely on active different at external their calcium.I type calpain (=μ calpain) is by the activation of the calcium ion of micro-molar concentration, and II type calpain (=m calpain) is only activated by the calcium ion of millimolar concentration.These two kinds of calpains are made up of 2 subunits of the subsection of the large subunit of 1 about 80kDa and 1 about 30kDa.2 subunits of activatory heterodimer have the calcium binding site.Large subunit comprise following 4 protein structure domains (=I-IV): 1 proteolytic enzyme structural domain (domain II), 1 calcium binding domains (=structural domain IV) and 2 unclear other structural domains of its function (=structural domain I and III).The little subunit of 30K by 1 calcium in conjunction with subunit (=IV ') and other 1 unclear subunit of its function (=V) form.Except these calpains of 2 types, in chicken, find (Wang K.K.W. etc., TiPS, 15 volumes in the third type that mediates aspect the calcium activation (=μ/m 80K), 1994:412-419, Suzuki, K etc., biological chemistry Hoppe-Seyler, 376 volumes, 1995:523-529).

Except these calpains that extensively distribute, identified the calpain of 2 kinds of novel organizing specific expressions recently.NCL-1 (=p94) be the calpain of muscle specific, be present among chicken, rat and the mankind, infer that it is as the monomer activation and only be made up of the subunit of 80kd.Except nCL-1, also existing may be with 2 kinds of stomach specific calpaines enzyme of shearing varient nCL-2 and nCL-2 ' appearance.NCL-2 ' is different with nCL-2 be to lack the calcium land (Sorimachi, H.S. etc., journal of biological chemistry 268 volumes, 26 phases, 1993:19476-19482, Sorimachi, H:S: etc., the FEBS communication, 343,1994:1-5).The homologous protein of the calpain of in fruit bat, finding (=CalpA), energy and Actin muscle interact, and may play an important role in fetal development, and it has 2 kinds of different splicing variants.In this case, short varient also lacks the calcium binding site.

Infer that calpain plays an important role in various physiological processs, many cytoskeletons, film in conjunction with or regulate albumen such as protein kinase C, Phospholipase C, spectrin, cytoskeletal protein such as MAP2, mytolin, neurofilament and neuropeptide, blood platelet albumen, Urogastron, nmda receptor and relate to mitotic albumen and other albumen, all are substrate (Barrett M.J. etc. of calpain, life science, 48,1991:1659-69, Wang K.K. etc., the pharmacology scientific advance, 15,1994:412-49).Yet the normal physiological function of calpain is not well understood to yet.They are relevant with the many physiological processs such as apoptosis, cell fission and differentiation or fetal development.

In various pathophysiological processes and imbalance, for example in heart ischemia (as myocardial infarction), renal ischaemia or central nervous system ischemic (as apoplexy), inflammation, muscular dystrophy, intraocular cataract (grey cataract), to central nervous system injury (as wound), alzheimer's disease, HIV inductive neuropathy, Parkinson's disease with enjoy the court of a feudal ruler and pause in the tarantism etc. (see and go up Wang K.K.), detected the level of the calpain that improves.Be related between the cellular calcium level of inferring these imbalances and raising and keeping.This causes calcium dependent process overactivity and controlled by physiology.Correspondingly, the overactivity of calpain also may start pathophysiological process.

This is to suppose that the inhibitor of calpain can be used for treating the reason of these imbalances why.Various research materials have also confirmed this point.Therefore; Seung-Chyul Hong etc. (apoplexy 1994,25 (3), 663-669) and (neuroscience research 1995 such as Bartus R.T.; 17,249-258) have neuroprotective in the acute neurological sexual maladjustment that the demonstration calpain inhibitor occurs after apoplexy.Similarly, after the experimental brain injury, calpain inhibitor improve the nervimotion imbalance of the loss of memory and appearance recovery (Saatman K.E. etc., institute of NAS newspaper 93,1996:3428-3433).Edalstein C.L. etc. (institute of NAS newspaper, 92,1995,7662-7666) find that calpain inhibitor has provide protection to the damage of the kidney that caused by hypoxemia.Yoshida K.I. etc. (Japanese circulation magazine, 59 (1), 1995,40-48) show that calpain inhibitor has useful effect to ischemic or behind the heart and injury that perfusion causes again.Because calpain inhibitor suppresses the proteic release of β-AP4, advised treatment to alzheimer's disease have the potential purposes (Higaki J. etc., neurone, 14,1995:651-659).The release of il-1 α suppressed by calpain inhibitor equally (Watanabe N. etc., cytokine, 6 (6), 1994:597-601).And find that calpain inhibitor has cytotoxicity (Shiba E. etc., the 20th international breast cancer research society conference, Sendai Japan, 1994,25-28, September, international tumour magazine 5 (supplementary issue), 1994,381) to tumour cell.Calpain also plays an important role in restenosis and sacroiliitis, thus calpain inhibitor to these sick pathology have useful effect (March K:L: etc., circulating research, 72,1993:413-423, Suzuki K. etc., journal of biological chemistry, 285,1992:857-862).

(pharmacology scientific advance 15 1994:412-419) has found the further of calpain inhibitor may purposes in the article of Wang K.K..

The most effective and optionally calpain inhibitor be the intracellular protein Calpastatin of natural generation.It can suppress I type calpain and II type calpain, but does not suppress such as other halfcystines and thiol group proteolytic enzyme such as cathepsin B, L or vegetable pepsins.Yet Calpastatin has the unfavorable characteristics that are not suitable for possible treatment, because its size is made up of about 700 amino acid, can not stride across cytolemma.Except low-molecular-weight calpain inhibiting peptide, identified the inhibitor of many non-peptides.The unfavorable characteristics of these inhibitor are that they can not be stablized, and promptly decomposed by metabolism, and wherein some have toxicity.In addition, many calpain inhibitor selectivity are not enough, that is, they not only suppress I and II type calpain, also suppress other L-Cysteine HCL Anhydrous such as vegetable pepsin, Quimotrase, Proteinase, bone marrow serine or cathepsin B and L.

Therefore, need to continue selectivity and highly effective calpain inhibitor.These selectivity and very effective calpain inhibitor screen in the mensuration system that also needs high special, so that identify optionally inhibitor.Usually carry out screening assay with the I type calpain and the II type calpain that extensively exist.

For finding selective depressant, the calpain that may be used to measure organizing specific expression further is provided, be necessary and meet the requirements, can in various calpains, measure its selectivity to described inhibitor like this.

In addition, further seek novel calpain,, and in these imbalances, play an important role because they very might be the albumen of differential expression in various pathology and imbalance.

An object of the present invention is to provide the method for difference and evaluation calpain inhibitor and the target thing of these inhibitor as treatment is provided, these methods only might identify on the one hand to a kind of calpain have restraining effect and/or, on the other hand polycalcium proteolytic enzyme is had inhibiting calpain inhibitor.

We find that purpose of the present invention is by a kind of novel tissue-specific calpain gene that sequence SEQID NO.1 or SEQ ID NO.3 name are called CAPN6 that has, its allelic variant, analogue or derivative and reach, at the deutero-amino acid levels, the homology of these analogues or derivative is from 60～100%, and wherein this calpain gene, their allelic variant, analogue or derivative contain following sequence:

(a)Leu-Gly-Asn-Lys-Ala，

Wherein corresponding sequence is different in this sequence and the people I type calpain, has changed into Methionin 81 of sequence SEQ ID NO.1 and SEQ ID NO.3 because be arranged in 115 amino acid cysteine in the people I type calpain;

(b)Ala-X-Ser-Cys-Leu-Ala，

Wherein, compare, changed among sequence SEQ ID NO.1 and the SEQ IDNO.3 88 and 91 s' Serine and L-Ala at 122 and 125 amino acid alanines and Threonine with corresponding sequence in the people I type calpain;

(c)Gly-Tyr-Thr-(His?oder?Tyr)-Thr-X-Thr，

Wherein, compare with corresponding sequence in the people I type calpain, 252,253 and 255 tyrosine, Threonine and Threonine have been changed in sequence SEQ ID NO.1 and SEQ ID NO.3 at 272,273 and 275 amino acid Histidine, L-Ala and Serine, in addition, in SEQ ID NO.3, change among the SEQ ID NO.3 254 Histidine at the tyrosine residues of 274 of I type calpains;

(d)Alg-X-Arg-Asn-Pro-Leu-Gly

Wherein this sequence is different with the corresponding sequence of people I type calpain, because in people I type proteolytic enzyme, be arranged in 286 the leucine that 298 amino acid tryptophan has been changed into sequence SEQ ID NO.1 and SEQ ID NO.3, and

X is any natural amino acid in described sequence.

The present invention also relates to a kind of method of differentiating calpain inhibitor, wherein by at calpain, its allelic variant or the analogue of the disclosed sequence encoding of claim 1 from tissue or cellular segregation, and measured cracking by test substances inhibitory enzyme CAPN6 substrate, and at least in other a mensuration, measured the cracking that is suppressed I and/or II type calpain substrate by test substances, having selected then can inhibitory enzyme CAPN6 and at least a other the test substances of calpain.

The invention further relates to a kind of method of differentiating calpain inhibitor, wherein determined in cell system by the cracking of test substances inhibitory enzyme CAPN6 substrate or the cracking of I and/or II type calpain substrate, and selected the material that passes cytolemma and inhibitory enzyme CAPN6 intracellular reactive and/or I and/or II calpain intracellular reactive, selected inhibitory enzyme CAPN6 not but suppressed the material of I and/or II type calpain, perhaps selected inhibitory enzyme CAPN6 but do not suppress I and/or the material of II calpain.Also advantageously selecting externally has activity to calpain but can not enter the material of the cell that is detected.If follow-up mensuration shows these materials and can not or only faintly enter cell that their cell permeability can improve by deriving method.

With BLAST method program (http://www.ncbi.nlm.nih.gov) in the est database at national biotechnology confidence center, personnel selection μ and m calpain gene order are sought its homology.Find one to have the calpain type sequence, be called as the sequence of ESTAA050030.May prepare the clone of a mouse with this sequence, the gene of its clones coding, its gene product is novel calpain, be called CAPN6 (=nCL-4).The nucleotide sequence of this clone nCL-4 can find in SEQ ID NO:1.The aminoacid sequence of the calpain CAPN6 that it is known by inference can find in SEQ ID NO:2.Consider the existence of intron, deduced amino acid is shown as typical calpain feature, although because low homology can not be referred to it in calpain subtribe of known μ calpain, m calpain, nCL-1 or nCL-2.Calpain CAPN6 is a kind of calpain of novel former the unknown.In est database, be used for further studying, the other 4 personal sector's sequences (AA169715, C17337, C16980 and T39424) that have homology with mouse CAPN6 sequence are provided from this sequence of mouse.These partial sequences can be assembled into a successive sequence, and coding length is 374 amino acid whose albumen.This sequence lacks typical methionine(Met) initiator codon and terminator codon.Therefore this sequence may only be that 374 the amino acid whose homologys of 2 sequences of partial sequence with people's orthologous gene of clone's mouse sequence are 94.9% (Fig. 1).

The protein sequence that derives from gene order SEQ ID NO:1 is shown as the homology with the whole aminoacid sequence 30% of Caenorhabditis elegans gene tra-3, and this is maximum homology.With the homology of other known calpains from 20.9% (rat nCL-2) to 25.4% (mouse m calpain).(Ktupl 2 with the Lipman-Pearson method, divide 4 at interval, gap length divides 12) sequence relatively in, CAPN6 and people CAPN1 (=CAN1-people, Aoki etc., FEBS communication 205,1986:313-317), people CAPN2 (=CAN2-people, Aoki etc., biological chemistry 27,1988:8122-8128), rat CAPN2 (=CAN2-rat, Deluca etc., biological chemistry Acta Biophysica Sinica 1216,1993:81-93), people CAPN3 (=CAN3-people, Richard etc., cell 81, (lacuna) 27-40), rat CAPN3 (=CAN3-rat, Sorimachi etc., journal of biological chemistry 264,1989:20106-20111) and the fruit bat calpain (=DMCLPNOCM-1) between, with regard to 230～520 amino acid whose partial sequences, find bigger slightly homology, be 32.8～39.5%, but with regard to the sequences of its whole comparisons, than the homology lower (Fig. 1, the coupling of usefulness PAM25 residue weight table is method in groups) of tra-3.Except tra-3, CAPN6 shows and the tangible homology of CAPN5 calpain (44.2% homology, document number p19718248.8) that discloses recently.

In various databases widely, the sequence between mouse and the people CAPN6 sequence is demonstration and CalpA, Tra-3 and the human sequence's who is called C16980, T39424, AA16971, R93331 and G17331 of its function information homology is not provided relatively.With the gene pool EST that is positioned at NCBI and database (http:Hwww.Ncbi.nlm.nih.yor) and Wash-U database (Homo Sapiens), carry out sequence relatively.In database, also find the mouse est sequence of AA050030 by name, and be denoted as calpain.Can not obtain further information from database.The complete genome sequence of AA16971T, R93331, C17331 and AA050030 is still unknown.

2 kinds of calpains (CAPN5 and CAPN6) have the common characteristic, can distinguish mutually with other calpains.Compare with other calpains, CAPN5 and CAPN6 not only have the structural domain I of a brachymemma, and have the C-end that does not have the modified of obvious homology with the structural domain IV of other calpains.The Ca of calpain ²⁺The consensus sequence of binding site (being called the EF hand) is positioned at structural domain IV district.This Ca ²⁺Binding site lacks in CAPN5 and CAPN6, and this means not to have Ca ²⁺Be attached on the structural domain IV, and these albumen activate in another way.Therefore, they are the vertebrates calpains that lack calmodulin spline structure territory IV.

Deutero-CAPN6 aminoacid sequence is another characteristics with the catalytic center of modified.Only 284 Asn residue is conservative.In mouse CAPN6 sequence, 81 cysteine residues and 252 s' histidine residues is replaced by Methionin and tyrosine respectively.(FEBS communication 205 1986:313-317) is compared for=CAPN1, Aoki etc., identifies the amino acid of further replacement in the catalytic center district for CAPN6 sequence SEQID NO.1 and SEQ ID NO.3 and people I type calpain.Therefore, 122 and 125 amino acid alanine and Threonine are changed among the CAPN6 88 and 91 Serine and L-Ala in CAPN1.Similarly, 272,273,275 and 298 amino acid Histidine, L-Ala, Serine and tryptophane are changed among the CAPN6 252,253,255 and 286 tyrosine, Threonine, Threonine and leucine among the CAPN1.Comparative sequences and the proteic conserved regions of coupling are carried out amino acid is matched each site of PROTEIN C APN1 and CAPN6, so on amino acid levels, are made to reach maximum consistent between the protein.Thereby possible, for example in protein family, identical sequence is positioned at very different sites or position in different albumen.

Except cysteine residues replaced, the tyrosine that people CAPN6 sequence is 254 was replaced (table 1) by Histidine.Perhaps, possible explanation is, for example CAPN6 has the substrate specificity different with other calpain, and perhaps this active center is inessential to the function of CAPN6, and it is a kind of inhibitor of other calpains, and perhaps CAPN6 is a kind of pseudogene.As if last a kind of possibility is impossible, because a large amount of conserved amino acids is arranged.Cysteine residues that might 89 can substitute the function of the cysteine residues of 81 disappearances in catalyzed reaction.Even CAPN6 do not have protease activity, and this is very impossible, and CAPN6 may and participate in regulate process with binding site on other calpains competition cofactors and the substrate.Table 1:CAPN6 genome sequence

The amino acid sequence number	?81 ^*	??89	?254 ^*	284 ^*	286 ¹
The amino acid sequence number	?81 ^*	??89	?254 ^*	284 ^*	286 ¹	Mouse CAPN6 (129 ES cell DNA)	??K	??C	??Y	??N	??L
People CAPN6 (HeLa cell DNA)	??K	??C	??H	??N	??L	Mouse CAPN6 (129 ES cell DNA)	??K	??C	??Y	??N	??L
People CAPN6 (HeLa cell DNA)	??K	??C	??H	??N	??L	Other calpains	??C	??S/C	??Y	??N	??W

^*(1995:397-400) 1 does not have leucine and activity very low (Arthur etc., FEBS communication to the amino acid in active centre in the m calpain for Arthur etc., FEBS communication 368

368，1995：397-400)

Tra-3 relates to sex determination in Caenorhabditis elegans.The cascade of the gene product of several genes relevant and they with tra-3 whether determine the male or telianthus of Caenorhabditis elegans grow (Kuwabara P.E. etc., TIG 8 volumes, 5 phases, 1992:164-168).As if Tra-3 relate to spermatogeny.In the various structural domains of mouse CAPN6 and tra3, be respectively 39.2%, 42.0%, 30.9% and 22% corresponding to the amino acid conservative property of structural domain I, II, III and T.

From deriving from the cDNA of (Ia) 17 mice embryonic mRNA, with (institute of NAS newspapers 25 such as Frohman, 1988,8998-9002) and (nucleic acids research 19 such as Edwards, 1991,5227-5232) the RACE of the modification of Miao Shuing (=rapid amplifying cDNA end) method, and with the above-mentioned primer of mentioning (Cal 6 and Cal 9) with derive from the sequence of ESTAA050030, may clone the complete sequence of the CAPN6 that is cloned.SEQ ID NO.1 coding has 641 amino acid, and molecular weight is the albumen of 74.6kDa.Be positioned at the methionine(Met) initiator codon by a classic sequence and begin translation before.The exactness of this sequence confirms by the order-checking that several cDNA with described sequence clone.

Fig. 2 show mouse CAPN5 (=nCL-3), people CAPN5 (=nCL-3), mouse CAPN6 (=nCL-4) and people CAPN6 (=homology between nCL-4).Fig. 2 also shows the sequence of Caenorhabditis elegans tra-3, people p94, mouse m calpain, people μ calpain and rat nCL-2.Amino acid consistent between various calpains and the CAPN6 is represented with black surround.Dotted line represents to obtain the gap of maximum sequence identity thereon.For for purpose of brevity, 2 sequences from people p94 sequence, have been lacked.These zone usefulness=signs.The conserved amino acid of catalytic center is represented with arrow.The aminoacid sequence that is equivalent to CAL6 and CAL9 underlines.The namelist of structural domain is shown the fragment of above-mentioned relevant sequence.

Fig. 3 shows the phylogenetic ancestry of various calpains.(Saitou etc., molecular biosciences chemical evolution 4,1987 406-425), are carried out Phylogenetic Analysis to make up this pedigree with getting rid of nearest neighbor method at interval.Result with these Phylogenetic Analysis assists down, the vertebrates calpain might be divided into 6 different groups (Fig. 3, right hand side).The invertebrates calpain as nearest neighbour albumen be referred to CAPN5-(=nCL-3-) and CAPN6-(=nCL-4-) organize and form their group.Therefore every kind of CAPN5 and CAPN6 gene form their calpain group, and this group is bigger than vertebrates calpain with the similarity of invertebrates calpain.Phylogenetic distance is proportional between horizontal length and the various calpain.The length of vertical line is nonsensical.The sequence that is used for constructing system growth pedigree has following SWISSPROT and EMBL sequence number (registration number): people m (p17655), μ (p07384), p94 (p20807); Rat m (Q07009), nCL-2 (D14480), p94 (p16259); Mouse p94 (X92523); Chicken m (D38026), μ (D38027), μ/m (p00789), p94 (D38028); Nematode tra-3 (U12921); Fruit bat Calp A (Q11002) and Dm (X78555), schistosomicide (p27730).The partial sequence of people nCL-2 is equivalent to the translation thing (Hellier etc., 1995, WashU-Merck EST planning) of EST clone AA026030.

According to this analysis, EST clone AA026030 deutero-aminoacid sequence is bigger than the general homology of rat nCL-2 sequence.Because only partial sequence is used for this analysis, the inaccuracy of the phylogenetic ancestry that nCL-2 is obtained is also bigger.Nematode CPL1 sequence is that (EMBOJ 1996,15:4477-4484) for the correction sequence used of Barnes and Hodjkin.

With 7 exons of first part, because they can obtain from EMBL database (registration number L25598), although 5 last exons can obtain until end by connection Nucleotide 8028-8133,8182-8239,8729-8818,8865-8963 and 9083.The deutero-N-of institute end sequence is because its length and many glycine residues are arranged is uncommon with regard to calpain.

Novel tissue-specific calpain CAPN6 only expresses (Fig. 4) at placenta tissue.The organ that people's placenta shows as quick growth and breaks up fast.Thereby also be considered to do " preceding malignant tissue, because it is it is height aggressive tissue, similar to the aggressive of malignant tumour.

Proteolytic enzyme plays central role in growth and cytodifferentiation, therefore also work in placenta, and placenta is rich in proteolytic enzyme and proteinase inhibitor, and the two locates equilibrium state, and placenta might be grown.As if CAPN6 plays an important role as proteolytic enzyme in this process, and/or may be relevant with the regulation and control of other halfcystine calpains.

Might this albumen with relevant such as the placenta pathologic process of gestosis (=preeclampsia), the gestosis incidence accounts for whole pregnant woman's 5～7%.Preeclampsia (=by conceived institute inductive hypertension) and be one of the most general complication of pregnancy period, it is characterized by high-pressure and proteinuria, usually with the over-drastic edema, in some cases, with convulsions.Be the major reason of mother and child's death the preeclampsia of gestation time, and the major reason of premature labor perhaps is the major reason that embryotrophy is bad or growth is lacked of proper care under slighter situation.This is multifactor incident, wherein relates to for example inherited genetic factors (recessiveness or dominant gene), mother's immunological tolerance, vascular relaxing factor/vasoconstrictive factor overbalance, and may also comprise CAPN6.

The women who suffers from preeclampsia changes the level of blood vessel pressurization peptide and angiotonase, and these two kinds of enzymes may be subjected to the influence of CAPN6 with regulative mode.

The possible function of another of CAPN6 may be regulated the degraded of somatostatin, glucagon and tethelin in placenta, and therefore influences the growth of fetus.The degraded of mother's serum protein of same stimulation fetal growth is influenced by CAPN6 also may.

Might relate to the complicated event of placenta mucous membrane in embryo's generation by CAPN6, and therefore for example regulate other calpains controls by TNF α and IFN γ inductive trophocyte apoptosis.Therefore, as if CAPN6 is relevant with fetal development.

In order to differentiate optionally calpain inhibitor, need to differentiate as far as possible specifically the method for inhibitor.Importantly selected in this regard inhibitor only suppresses desired calpain, but does not suppress other L-Cysteine HCL Anhydrouss, thereby disturbs physiological process.Waiting to study it, to suppress active test substances for example may be chemical substance, microorganism or plant milk extract.Except measuring it is suppressed the activity of CAPN6, I type and/or II type calpain, generally also measure their inhibition activity cathepsin B or other thiol proteinases.Ideally, good inhibitor should show faint or do not have an activity to cathepsin B, L, Proteinase, bone marrow serine, vegetable pepsin, Quimotrase or other L-Cysteine HCL Anhydrouss, but shows that I and II type calpain are had good activity.

According to the present invention, might be used to novel tissue-specific calpain CAPN6 to differentiate the method for inhibitor, this method can comprise its restraining effect of difference between the various calpains of calpain I, II, nCL-1, nCL-2 and/or nCL-4.

For this purpose, carrying out various inhibitor by following method measures:

Cathepsin B measures

By with S.Hasnain etc., journal of biological chemistry 268,1993,235-240 are described similar methods, measure the restraining effect of cathepsin B.

The inhibitor solution 2 μ l and the DMSO (final concentration: 100 μ M-0.01 μ M) that prepare chemical substance, microorganism or plant extract to be detected, being added in the 88 μ l cathepsin B liquid (provides the cathepsin B that derives from people's liver by Calbiochem company, is diluted to 5 units with 500 μ M damping fluids).This mixed solution is (=25 ℃) incubation 60 minutes in advance at room temperature, adds 10 μ l 10mM Z-Arg-Arg-pNA (being dissolved in the damping fluid with 10%DMSO) then and begins reaction.405nM carries out this reaction 30 minutes on the titer plate readout instrument.Determine IC according to the slope of maximum then ₅₀Value.

I and II type calpain are measured

(Merck Darmstadt) in the colorimetric estimation as substrate, studies the activity of calpain inhibitor using the Hammarsten casein.At analytical biochemistry 208,1993, the method for delivering among the 387-392 carry out this mensuration in titer plate according to Buroker-kilgore and Wang.Used enzyme is that two kinds of enzymes are all produced from pig, are provided by Calbiochem company from erythrocytic I type calpain (0.04U/ mensuration) with from the II type calpain (0.2U/ mensuration) of kidney.Material to be determined and described enzyme be incubation 60 minutes at room temperature, and the concentration of solvent DMSO is no more than 1%.After adding the Bio-Rad developer, 595nm measures optical density(OD) in SLT Eas/ readout instrument EAR 400.Described enzyme 50% active when not having inhibitor the maximum activity of this enzyme and the optical density value that this enzymic activity is measured when not adding calcium determine.

In addition, survey the activity of calpain inhibitor with substrate Suc-Leu-Tyr-AMC.This fluorimetry is by Zhaozhao Li etc., and journal of medicinal chemistry 36,1993 is described among the 3472-3480.

Because calpain is intracellular cysteine proteolytic enzyme, cytolemma must can be passed for proteinase inhibitor, so that prevent the degraded of the intracellular protein that causes by calpain.Some known calpain inhibitor such as E64 and the bright only less permeate through cell membranes of proteolytic enzyme that presses down, therefore, although they are good calpain inhibitors, pair cell only has faint influence.Therefore, carry out the ability that other mensuration detects potential calpain inhibitor permeate through cell membranes, it is favourable measuring as human blood platelets.

Thrombocyte is measured the intracellular reactive of determining calpain inhibitor.

The proteolytic degradation of calpain mediation is pressed Zhaozhao Li etc. in thrombocyte, journal of medicinal chemistry, and 36,1993, the described method of 3472-3480 is carried out.Human blood platelets separates the fresh Trisodium Citrate blood that free donor provides, and (5mM hepes, 140mMNaCl and 1mg/ml BSA pH7.3) are adjusted to 10 to use damping fluid then ⁷Cell/ml.

Thrombocyte (O.1ml) was potential inhibitor (being dissolved among the DMSO) preincubation of the various concentration of 1 μ l 5 minutes.Add Calcium ionophore A 23187 (1 μ M in the mensuration) and calcium (5mM in the mensuration) then, 37 ℃ of further incubations are 5 minutes then.After centrifugation step, thrombocyte is dispersed in the SDS-PAGE sample buffer, and 95 ℃ were boiled 5 minutes then, and described albumen separates in 8% gel.2 kinds of albumen actin binding protein (=ABP) and the degraded situation of talin carry out with the number density assay method.After adding calcium and ionophore, these albumen disappear, and the new swimming band that molecular weight is lower than 200kd but occurs.Determine inhibiting or a half value of the maximum enzyme activity of inhibiting not in contrast thus.

The material that is suitable for measuring the permeate through cell membranes ability equally is portion of tissue or the cell culture as brain section.

Carry out suppressing being determined in this proteic cell of expression of CAPN6, from allowing with this albumen of special antibody test.If cell is stimulated by for example calcium and suitable ionophore, this causes the activation of CAPN6.Takaomi Saido is at journal of biological chemistry 11,1992, describes the self cracked conversion of activation back μ calpain among the 81-86 and with the result of antibody test.Produced the suitable antibodies that detects CAPN6.Calpain inhibitor stop the self cracked conversion and corresponding qualitative be possible with antibody.

Except the external test and cell thrombocyte mensuration described, it all is suitable that all other calpains that the technician is known are measured, for example in cortical neuron, suppress the necrocytosis of glutamine inductive and measure (Journal of Neuroscience such as Maulucci-Gedde M.A., 7,1987:357-368), (SquierM.K.T. etc., stechiology magazine 159 are measured in the necrocytosis of calcium mediation in the NT2 cell, 1994:229-237, Patel T. etc., Faseb magazine, 590,1996:587-597), or to tissue sample such as spectrin, analysis (the Ami Arai etc. of proteolytic degradation such as MAPZ or tau product, brain research, 1991,555,276-280, James Brorson etc., apoplexy, 1995,26,1259-1267).

Measure for external CAPN6; purifying calpain or its animal or human's class homologue or the tissue of artificial (as passing through recombination and expression techniques) or the tissue normal from this enzyme; placenta advantageously for example; perhaps from contain 1 gene copy at least and/or have the cell of CAPN6 gene, its allelic variant or analogue of at least 1 copy or microorganism purifying, and with the purifying thing as crude extract or as pure enzyme.

The method according to this invention, all calpain inhibitors measure and the mensuration that suppresses the CAPN6 enzymic activity by potential inhibitor in conjunction with being favourable.This is necessary to select inhibitory enzyme CAPN6 only not suppress the inhibitor of other calpains, otherwise or, only suppress other calpains but inhibitory enzyme CAPN6 or suppress the inhibitor of CAPN6 or at least a other calpains not.It is favourable that the CAPN6 inhibitor is used in the disease of gestosis.

Moreover various inhibitor are measured and are carried out in such a way, except measuring the restraining effect of institute's test substances to CAPN6, I and/or II calpain, in contrast, are not determined at when having test substances and carry out.This mensuration arrangement detects the restraining effect of institute's test substances easily.

Another kind of the method according to this invention is preferably with CAPN6 or its allelic variant, analogue or synthesis of derivatives, to protect the enzymolysis of other calpains.

Another kind of the method according to this invention is to use the novel calpain inhibitor of enzyme CAPN6 screening, and these inhibitor generally can suppress all calpains significantly or suppress single calpain of planting such as calpain I, II, nCL-1, nCL-2 or CAPN6 etc.Moreover various tester mass-energy are independent or replicate(determination) in detection system.Preferably in parallel automatic checkout system, screen these test substances from their restraining effect.

In general, all substances are applicable to inhibitor mensuration.Therefore, described material derives from for example classical chemosynthesis, derives from combinatorial chemistry or derive from microorganism, animal or plant extract.The microorganism extract refers to, for example the material of smudge cells of fermented liquid, microorganism or bio-transformation.Cell each several part isolate also is suitable for measuring.

Be applicable to that clone's CAPN6 gene or its animal homologue or its people's homologue, its allelic variant or analogue are that all are applicable to protokaryon or the eukaryotic expression system that separates the enzymolysis activity gene product.Preferred expression system is those those systems that allow the CAPN6 gene order to express in bacterium, fungi or zooblast, very particularly preferably in expressed in insect cells.The enzymolysis activity gene product means that for example protokaryon or eukaryotic cell separate the back or directly be provided as CAPN6 albumen after the renaturation again from expressing biology, activated protein is a kind of those known calpain substrates as mentioned above of cracking at least, or autocatalysis effect self.

The mensuration that is applicable to the enzymic activity of determining calpain is those methods that institute is known the technician, for example above-described external test method that I and II type calpain are measured, or as the raji cell assay Raji of thrombocyte mensuration.May be used to detect be according to colorimetry (Buroker-Kilgore M. etc., analytical biochemistry, 208,1993:387-392) or the assay method of fluorescent method.

In addition, the enzymolysis activity gene product of CAPN6 also means all partial sequences of the catalytic center of other sequences of containing CAPN6 gene and/or CAPN6 gene and/or other calpain gene orders and/or other sequences, and is shown as enzymolysis activity.

Mean all protokaryons or the eukaryote that is suitable for as host living beings as for host living beings, bacteriums such as intestinal bacteria, subtilis, shallow Streptomyces glaucoviolaceus, Streptococcus carnosus for example, as yeast such as yeast saccharomyces cerevisiae, fission yeasts, as fungies such as aspergillus nigers, be suitable for other insect cells of viral expression as insect cells such as fall army worm, cabbage looper cell or all, perhaps as the zooblast of CV1, COS, C127,3T3 or CHO etc., or people's cell.

Mean as for expression system above-mentioned by mention biological of embodiment form with to the combination of described biological suitable carriers, these carriers such as plasmid, virus or as the phage of T7 RNA polymerase/promoter systems or have carrier to lambda particles phage adjusting sequence.

Term expresses that optimum system choosing ground refers to intestinal bacteria and its plasmid and phage or rhabdovirus system and correspondingly such as the composition of meadow pretty young woman's at night insect cell.

In addition, other 3 ' and/or 5 ' end sequence be used for the better expression of CAPN6 gene according to the present invention.

Use these purposes of regulating sequence to make the specifically expressing of CAPN6 gene become possibility.This means that for example only importing the back according to the described gene of host living beings expresses or cross expression, perhaps it is expressed immediately and/or crosses and express.

Moreover, regulate sequence and the factor may preferably genetic expression has favorable influence to CAPN6, and thereby increase the CAPN6 expression of gene.Therefore, by use such as promotor and/or enhanser transcribe signal by force, regulatory element is enhanced valuably at transcriptional level.Yet, in addition, for example also may strengthen translation effect by the stability of improving mRNA.

Enhanser refers to, and for example interaction by improving between RNA polymerase and the DNA causes increasing the dna sequence dna of CAPN6 genetic expression.

One or more dna sequence dna may be positioned at before the CAPN6 gene and/or the back, and this CAPN6 gene has before or is not activated son and has or do not have regulatory gene, and this gene exists in the gene structure like this.

In addition, can increase the CAPN6 expression of gene by the copy number that increases the CAPN6 gene.The copy number of CAPN6 gene is for example increased by amplification in the CHO expression vector.Suitable carriers also is that pED serial carrier-bicistronic mRNA carrier-this carrier also contains the dihydrofolate dehydrogenase marker gene that can increase.Introduction can be found in 1994, one books at molecular biology present age method the 2nd volume in detail.

Compare with initial enzyme increase the CAPN6 enzymic activity can be by for example modifying the CAPN6 gene or its animal homologue obtains, these modifying method are classical mutagenesis such as uv-radiation or handle with chemical mutagen, and/or special mutagenesis such as site-directed mutagenesis, disappearance, insertion and/or replacement.Enzymic activity for example can increase by modifying catalytic center, therefore obtains to treat the faster turnover ratio of cracking substrate.Except described gene amplification method, increasing enzymic activity also can be by eliminating the biosynthetic factor of inhibitory enzyme and/or obtaining in nonactive CAPN6 albumen position composite reactive part.In this way, may be provided for the enzyme amount that external test increases.

CNPA6 or its animal homologue or its people's homologue can for example use pcr clone (to see molecular cloning, Sambrook preferably from gene DNA or cDNA, Fritsch and Maniatis, cold spring port, laboratory press, second edition 1989,14 chapter 1-35, ISBN0-87969-309-6 and Saili etc., science 239,1988,487 and following), CAPN6 can preferably use genomic dna cloning, particularly preferably is used for genomic dna cloning from mouse cell or people's cell.

Being suitable for use as clone's host living beings, for example is whole coli strains, preferred coli strain DH10B.The suitable carrier that is used to clone is that all are suitable for the carrier (seeing molecular cloning, Sambrook, Fritsch and Maniatis, cold spring port, laboratory press, second edition, 1989, ISBN 0-87969-309-6) at expression in escherichia coli.Specially suitable embodiment is the carrier that derives from pBR or pUC, or shuttle vectors, and pBlubecripf is very specially suitable.

What separation and order-checking back obtained is the CAPN6 gene with the nucleotide sequence that is coded in the aminoacid sequence that shows among the SEQ ID NO:2, or its allelic variant.Mean that as for allelic variant the CAPN6 variant has at the homology of amino acid levels from 60-100%, preferably 70-100%, very particularly preferably 80-100%.Allelic variant comprises especially can be from the sequence of representing among SEQ ID NO:1 or SEQ ID NO:3, disappearance, insertion or replacement by Nucleotide but still keep the active functional variant that obtains of CAPN6, sequence (a) Leu-Gly-Asn-Lys-Ala, (b) Ala-X-Ser-Cys-Leu-Ala, (c) Gly-Tyr-Thr (His or Tyr)-Thr-X-Thr and (d) Arg-X-Arg-Asn-Pro-Leu-Gly also be present in CAPN6 gene, analogue or the derivative.

Refer to as for the CAPN6 analogue, for example the RNA of sequence, single stranded DNA or the coding of its animal homologue, brachymemma and noncoding dna sequence dna, especially sense-rna.

The example of CAPN6 derivative is those derivatives that are difficult to enzymatic lysis or only slight enzymolysis, and for example phosphatase nucleic acid ester or nucleic acid thiophosphatephosphorothioate, the phosphate group of its amplifying nucleic acid phosphonate ester or thioester group replace.

The promotor that exists before described nucleotide sequence also can and/or lack by one or more Nucleotide exchanges, insertion, but does not damage the functional or active method modification of promotor.In addition, the activity that this promotor had can be by modifying its sequence, or fully by in addition derive from the more active promotor of the biological or synthetic origin of allos and increase.

The calpain inhibitor that the method according to this invention is differentiated is applicable to produces medicine with the treatment imbalance relevant with the calpain dysfunction, for example treatment is selected from cardiovascular diseases, the immunology disease, inflammation, anaphylactia, nervous system disease, nerve degenerative diseases or tumour, these diseases such as restenosis, sacroiliitis, heart ischemia, renal ischaemia or central nervous system ischemic (as apoplexy), inflammation, amyotrophy, intraocular cataract (as the grey cataract), damage (as wound) to central nervous system, alzheimer's disease, HIV inductive neuropathy, Parkinson's disease and enjoying are prolonged a tarantism, preferably produce medicine and are used for the treatment of such as imbalance of placentas such as gestosis or embryo and lack of proper care.

According to the present invention, the CAPN6 gene order also preferably is applicable to the various imbalances of diagnosis or is used for gene therapy.

Embodiment

The clone of embodiment 1:CAPN6 gene

Mouse CAPN6 sequence (EMBL registration number Y12583) is by applying marking 17 mice embryonics and the primer sequence that derives from EST AA050030 sequence, and the clone obtains through the RACE method.Containing the plasmid clone that is equivalent to est sequence obtains from I.M.A.G.E alliance (genetic research international corporation).In est database, search for homology with murine protein sequence and tblastn algorithm, obtain people CAPN6 homologue.The partial sequence that finds is combined the incomplete people CAPN6 sequence (SEQ IDNO:3) that may obtain having 1083 length of nucleotides.

Embodiment 2: CAPN6 expression of gene in various tissues

With ³²The people cDNA fragment of P mark and Clontech company provide contains people RNA master blotting membrane from 50 different tissues RNA, detects CAPN6 expression of gene in various tissues.Hybridization and highly strict cleaning condition carry out according to the explanation of producer.The CAPN6 cDNA fragment that is used to express experiment is the 2.2kbEcoRI/XhoI fragment that comprises EST AA050030.CAPN6 only expresses (see figure 4) in placenta tissue.In contrast, in order to determine the applied sample amount of RNA, this blotting membrane personnel selection ubiquitin DNA sample is hybridized.

The location of embodiment 3:CAPN6 gene on karyomit(e).

With NIGMS people/rodents somatic hybridization " mapping group " (Coriell cell repository) system location people's gene.The primer sequence that is used for PCR is as follows: 5 ' gttgaaactgattggggtctg-3 ' and 5 '-ctgtcttcccaaggggtttctc-3 '.Pcr amplification carries out for 58 ℃ with annealing temperature, and produces the fragment of a 200bp.There is consistency desired result between fragment and the PCR product in the result by human chromosome.Also PCR result is passed to Stamford people's gene group switching centre locating service mechanism (http://www-shgc.stanford.edu) with Stamford G3 RH group (genetic research company), find the accurate location of this gene in human chromosome.People CAPN6 gene finds on X chromosome, and joins with DXS7356 mark coupling.

Embodiment 4: cathepsin B measures

With with S.Hasnain etc., journal of biological chemistry, 268,1993, the similarity method that 235-240 describes is determined the restraining effect of cathepsin B.

Preparation is from the 2 μ l inhibitor solutions of inhibitor and DMSO (final concentration: 100 μ M～0.01 μ M) be added to that (cathepsin B is from people's liver in the 88 μ l cathepsin B liquid, provide by Calbiochem company, in 500 μ M damping fluids, be diluted to 5 units).This mixed solution is (=25 ℃) incubation 60 minutes in advance at room temperature, adds 10 μ l 10mM Z-Arg-Arg-pNA (being dissolved in the damping fluid with 10%DMSO) then and begins reaction.405nm reacted 30 minutes on the titer plate readout instrument.Determine IC according to the slope value of maximum then ₅₀Value.

Embodiment 5: calpain is measured

With colorimetric method and Hammarsten casein (Merck, Darmstadf) as substrate, the activity of research calpain inhibitor.At analytical biochemistry 208,1993, the method for delivering among the 387-392 carry out this mensuration in titer plate according to Buroker-Kilgore and Wang.Used enzyme is to express the CAPN6 of purifying then in one of above-described system.Described material and this enzyme be incubation 60 minutes at room temperature, and the concentration of solvent DMSO is no more than 1%.After adding the Bio-Rad developer, in SLT Easy Reader EAR 400, measure optical density(OD) with 595nM.The maximum activity of this enzyme and the activity of this enzyme is measured when not adding calcium optical density value during according to inhibiting are not determined 50% activity of this enzyme.

Embodiment 6: thrombocyte is measured to determine the cytoactive of calpain inhibitor.

Press journal of medicinal chemistry 36,1993 such as zhaozhao Li, the method for describing among the 3472-3480 is carried out the proteolytic degradation experiment in the thrombocyte of calpain mediation.Human blood platelets always separates in the fresh Trisodium Citrate blood of donor, and (5mM Hepes, 140mM NaCl and 1mg/ml BSA pH7.3) are adjusted to 10 to use damping fluid then ⁷Cell/ml.

Thrombocyte (0.1ml) is at the inhibitor (being dissolved among the DMSO) (SiC) of the various concentration of 1 μ l incubation 5 minutes in advance.Add calcium ion carrier A 23187 (1 μ M in mensuration) and calcium (5mM in mensuration) then, 37 ℃ of further incubations 5 minutes.After centrifugation step, thrombocyte is dissolved in the SDS-page sample buffer, boils protein isolate in 8% gel 5 minutes at 95 ℃ then.By the number density method detect 2 kinds of albumen actin binding protein (=ABP) and talin degraded, because after adding calcium and ionophore, these albumen disappear.At the 200kd molecular weight area a new band appears then.According to this method, determine a half value of maximum enzyme activity.

Sequence table

(1) physical data

(i) applicant:

(A) name: BASF Aktiengesellschaft

(B) street: Carl Bosch Strasse

(C) city: Ludwigshafen

(D) state: Rheinland-Pfalz

(E) country: Germany

(F) postcode: D-67056 (ii) applies for exercise question: novel tissue-specific calpaines enzyme, these proteic preparations

Method and purposes be sequence number (iii): 4 (iv) computer-readable data:

(A) media type: Floppy floppy disk

(B) computer: IBM PC compatibility

(C) operating system: PC-DOS/MS-DOS

(D) software: the data of PateatIn Release#1.0 Version#1.25 (EPO) (2) SEQ ID NO:1: (i) sequence signature:

(A) length: 2069 base pairs

(B) type: nucleic acid

(C) chain: strand

(D) topology: linearity

(ii) molecule type: DNA (genomic)

(iii) hypothetical structure: do not have

(iii) antisense sequences: do not have

(vi) biogenetic derivation:

(A) biology: house mouse

(vii) direct sources:

(B) clone: CAPN6

(ix) feature:

(A) title/keyword: 5 ' UTR

(B) location: 1..129

(ix) feature

(A) title/keyword: CDS

(B) location: 130..2055

(ix) feature:

(A) title/keyword: 3 ' UTR

(B) location: 2.056..2069

(xi) sequence description: SEQ ID NO:1GGGGTTACCT GGCTAAGAGC AGCAGCAGCA GCAGCAGCAG CAGCAGCAGT AGCAGCAGCA 60GCAGCAGCAG CAGCAGCAGC AGCAGCAGCA GCAGGGTTCC TGAGCTAACT CAGACCTAGT 120TTGATAGCA ATG GGT CCT CCT CTG AAG CTC TTC AAA AAC CAG AAG TAC 168

Met?Gly?Pro?Pro?Leu?Lys?Leu?Phe?Lys?Asn?Gln?Lys?Tyr

1???????????????5??????????????????10CAA?GAA?CTG?AAG?CAG?GAG?TGC?ATG?AAG?GAT?GGC?CGC?CTT?TTC?TGT?GAC???????216Gln?Glu?Leu?Lys?Gln?Glu?Cys?Met?Lys?Asp?Gly?Arg?Leu?Phe?Cys?Asp

15??????????????????20??????????????????25CCA?ACC?TTC?CTA?CCG?GAG?AAT?GAT?TCT?CTG?TTT?TTC?AAC?CGG?CTG?CTT???????264Pro?Thr?Phe?Leu?Pro?Glu?Asn?Asp?Ser?Leu?Phe?Phe?Asn?Arg?Leu?Leu?30??????????????????35??????????????????40??????????????????45CCT?GGG?AAG?GTG?GTG?TGG?AAG?CGT?CCA?CAG?GAC?ATT?TCT?GAT?GAC?CCC???????312Pro?Gly?Lys?Val?Val?Trp?Lys?Arg?Pro?Gln?Asp?Ile?Ser?Asp?Asp?Pro

50??????????????????55??????????????????60CAC?CTG?ATT?GTG?GGC?AAC?ATC?AGC?AAC?CAC?CAG?CTG?ATC?CAG?GGC?AGA???????360His?Leu?Ile?Val?Gly?Asn?Ile?Ser?Asn?His?Gln?Leu?Ile?Gln?Gly?Arg

65??????????????????70??????????????????75TTG?GGG?AAC?AAG?GCA?ATG?ATC?TCT?GCA?TTT?TCC?TGT?TTG?GCT?GTT?CAG???????408Leu?Gly?Asn?Lys?Ala?Met?Ile?Ser?Ala?Phe?Ser?Cys?Leu?Ala?Val?Gln

80??????????????????85??????????????????90GAG?TCA?CAC?TGG?ACA?AAG?GCA?ATT?CCC?AAC?CAC?AAG?GAT?CAG?GAA?TGG???????456Glu?Ser?His?Trp?Thr?Lys?Ala?Ile?Pro?Asn?His?Lys?Asp?Gln?Glu?Trp

95?????????????????100?????????????????105GAT?CCT?CGA?AAG?CCA?GAG?AAA?TAC?GCT?GGA?ATC?TTT?CAC?TTC?CGC?TTC???????504Asp?Pro?Arg?Lys?Pro?Glu?Lys?Tyr?Ala?Gly?Ile?Phe?His?Phe?Arg?Phe110?????????????????115?????????????????120?????????????????125TGG?CAT?TTT?GGA?GAA?TGG?ACC?GAG?GTG?GTG?ATT?GAT?GAC?TTG?CTT?CCC???????552Trp?His?Phe?Gly?Glu?Trp?Thr?Glu?Val?Val?Ile?Asp?Asp?Leu?Leu?Pro

130?????????????????135?????????????????140ACC?ATC?AAC?GGA?GAT?CTG?GTC?TTC?TCA?TTC?TCC?ACC?TCC?ATG?AAT?GAG???????600Thr?Ile?Asn?Gly?Asp?Leu?Val?Phe?Ser?Phe?Ser?Thr?Ser?Met?Asn?Glu

145?????????????????150?????????????????155TTT?TGG?AAT?GCT?CTA?CTG?GAA?AAA?GCG?TAT?GCA?AAG?CTG?CTG?GGC?TGT???????648Phe?Trp?Asn?Ala?Leu?Leu?Glu?Lys?Ala?Tyr?Ala?Lys?Leu?Leu?Gly?Cys

160?????????????????165?????????????????170TAT?GAG?GCT?TTG?GAT?GGT?CTG?ACC?ATC?ACT?GAT?ATC?ATC?ATG?GAC?TTC????????696Tyr?Glu?Ala?Leu?Asp?Gly?Leu?Thr?Ile?Thr?Asp?Ile?Ile?Met?Asp?Phe

175?????????????????180?????????????????185ACT?GGC?ACA?CTG?GCT?GAA?ATC?ATT?GAC?ATG?CAG?AAA?GGA?CGA?TAC?ACT????????744Thr?Gly?Thr?Leu?Ala?Glu?Ile?Ile?Asp?Met?Gln?Lys?Gly?Arg?Tyr?Thr190?????????????????195?????????????????200?????????????????205GAT?CTT?GTT?GAG?GAG?AAG?TAC?AAG?CTG?TTT?GGA?GAA?CTG?TAC?AAA?ACG????????792Asp?Leu?Val?Glu?Glu?Lys?Tyr?Lys?Leu?Phe?Gly?Glu?Leu?Tyr?Lys?Thr

210?????????????????215?????????????????220TTC?ACC?AAA?GGA?GGT?CTA?ATT?TGC?TGC?TCC?ATT?GAG?TCT?CCC?AGC?CAG????????840Phe?Thr?Lys?Gly?Gly?Leu?Ile?Cys?Cys?Ser?Ile?Glu?Ser?Pro?Ser?Gln

225?????????????????230?????????????????235GAG?GAA?CAA?GAA?GTT?GAA?ACA?GAC?TGG?GGA?CTA?CTG?AAG?GGT?TAT?ACC????????888Glu?Glu?Gln?Glu?Val?Glu?Thr?Asp?Trp?Gly?Leu?Leu?Lys?Gly?Tyr?Thr

240?????????????????245?????????????????250TAC?ACC?ATG?ACT?GAT?ATT?CGC?AAG?CTC?CGT?CTC?GGA?GAA?AGA?CTT?GTG????????936Tyr?Thr?Mat?Thr?Asp?Ile?Arg?Lys?Leu?Arg?Leu?Gly?Glu?Arg?Leu?Val

255?????????????????260?????????????????265GAA?GTC?TTC?AGT?ACT?GAG?AAG?CTG?TAT?ATG?GTT?CGC?CTA?AGG?AAC?CCA????????984Glu?Val?Phe?Ser?Thr?Glu?Lys?Leu?Tyr?Met?Val?Arg?Leu?Arg?Asn?Pro270?????????????????275?????????????????280?????????????????285TTG?GGA?AGA?CAG?GAA?TGG?AGT?GGC?CCC?TGG?AGT?GAA?ATT?TCA?GAG?GAG???????1032Leu?Gly?Arg?Gln?Glu?Trp?Ser?Gly?Pro?Trp?Ser?Glu?Ile?Ser?Glu?Glu

290?????????????????295?????????????????300TGG?CAG?CAA?CTG?ACT?GTA?ACA?GAT?CGC?AAG?AAC?CTA?GGA?CTT?GTT?ATG???????1080Trp?Gln?Gln?Leu?Thr?Val?Thr?Asp?Arg?Lys?Asn?Leu?Gly?Leu?Val?Met

305?????????????????310?????????????????315TCT?GAT?GAT?GGA?GAA?TTT?TGG?ATG?AGT?CTG?GAA?GAT?TTT?TGC?CAC?AAC???????1128Ser?Asp?Asp?Gly?Glu?Phe?Trp?Met?Ser?Leu?Glu?Asp?Phe?Cys?His?Asn

320?????????????????325?????????????????330TTT?CAC?AAA?CTG?AAT?GTC?TGC?CGC?AAT?GTG?AAT?AAT?CCT?GTT?TTT?GGC???????1176Phe?His?Lys?Leu?Asn?Val?Cys?Arg?Asn?Val?Asn?Asn?Pro?Val?Phe?Gly

335?????????????????340?????????????????345CGC?AAG?GAG?CTG?GAA?TCA?GTG?GTG?GGA?TGT?TGG?ACT?GTG?GAT?GAT?GAC???????1224Arg?Lys?Glu?Leu?Glu?Ser?Val?Val?Gly?Cys?Trp?Thr?Val?Asp?Asp?Asp350?????????????????355?????????????????360?????????????????365CCT?CTG?ATG?AAC?CGA?TCA?GGA?GGT?TGC?TAT?AAC?AAC?CGT?GAT?ACC?TTC???????1272Pro?Leu?Met?Asn?Arg?Ser?Gly?Gly?Cys?Tyr?Asn?Asn?Arg?Asp?Thr?Phe

370?????????????????375?????????????????380TTG?CAG?AAT?CCT?CAG?TAC?ATT?TTC?ACT?GTG?CCC?GAG?GAT?GGC?CAT?AAA??????1320Leu?Gln?Asn?Pro?Gln?Tyr?Ile?Phe?Thr?Val?Pro?Glu?Asp?Gly?His?Lys

385?????????????????390?????????????????395GTC?ATC?ATG?TCA?CTG?CAA?CAG?AAG?GAC?CTA?CGC?ACT?TAC?CGC?CGA?ATG??????1368Val?Ile?Met?Ser?Leu?Gln?Gln?Lys?Asp?Leu?Arg?Thr?Tyr?Arg?Arg?Met

400?????????????????405?????????????????410GGA?AGA?CCT?GAT?AAT?TAC?ATC?ATT?GGT?TTT?GAG?CTC?TTC?AAG?GTG?GAG??????1416Gly?Arg?Pro?Asp?Asn?Tyr?Ile?Ile?Gly?Phe?Glu?Leu?Phe?Lys?Val?Glu

415?????????????????420?????????????????425ATG?AAC?CGA?AGG?TTC?CGT?CTT?CAC?CAT?CTG?TAT?ATT?CAG?GAG?CGT?GCT??????1464Met?Asn?Arg?Arg?Phe?Arg?Leu?His?His?Leu?Tyr?Ile?Gln?Glu?Arg?Ala430?????????????????435?????????????????440?????????????????445GGG?ACT?TCC?ACT?TAT?ATC?GAC?ACC?CGT?ACT?GTG?TTT?CTG?AGC?AAG?TAT??????1512Gly?Thr?Ser?Thr?Tyr?Ile?Asp?Thr?Arg?Thr?Val?Phe?Leu?Ser?Lys?Tyr

450?????????????????455?????????????????460CTG?AAG?AAG?GGC?AGC?TAC?GTG?CTT?GTT?CCA?ACC?ATG?TTC?CAA?CAT?GGC??????1560Leu?Lys?Lys?Gly?Ser?Tyr?Val?Leu?Val?Pro?Thr?Met?Phe?Gln?His?Gly

465?????????????????470?????????????????475CGT?ACC?AGT?GAA?TTT?CTG?CTG?AGG?ATC?TTC?TCT?GAA?GTG?CCC?GTC?CAG??????1608Arg?Thr?Ser?Glu?Phe?Leu?Leu?Arg?Ile?Phe?Ser?Glu?Val?Pro?Val?Gln

480?????????????????485?????????????????490CTC?AGG?GAA?CTG?ACC?TTG?GAC?ATG?CCC?AAG?ATG?TCT?TGC?TGG?AAC?CTG??????1656Leu?Arg?Glu?Leu?Thr?Leu?Asp?Met?Pro?Lys?Met?Ser?Cys?Trp?Asn?Leu

495?????????????????500?????????????????505GCA?CGT?GGC?TAC?CCA?AAG?GTG?GTT?ACC?CAG?ATC?ACT?GTC?CAC?AGT?GCT??????1704Ala?Arg?Gly?Tyr?Pro?Lys?Val?Val?Thr?Gln?Ile?Thr?Val?His?Ser?Ala510?????????????????515?????????????????520?????????????????525GAG?GGC?CTG?GAG?AAG?AAG?TAT?GCC?AAT?GAA?ACT?GTC?AAT?CCA?TAT?CTG??????1752Glu?Gly?Leu?Glu?Lys?Lys?Tyr?Ala?Asn?Glu?Thr?Val?Asn?Pro?Tyr?Leu

530?????????????????535?????????????????540ATC?ATC?AAA?TGT?GGA?AAG?GAG?GAA?GTC?CGT?TCC?CCT?GTC?CAG?AAG?AAT??????1800Ile?Ile?Lys?Cys?Gly?Lys?Glu?Glu?Val?Arg?Ser?Pro?Val?Gln?Lys?Asn

545?????????????????550?????????????????555ACT?GTG?CAT?GCC?ATT?TTT?GAC?ACG?CAG?GCC?GTT?TTC?TAC?AGA?AGG?ACC??????1848Thr?Val?His?Ala?Ile?Phe?Asp?Thr?Gln?Ala?Val?Phe?Tyr?Arg?Arg?Thr

560?????????????????565?????????????????570ACT?GAC?ATT?CCT?ATT?ATC?ATC?CAG?GTG?TGG?AAC?AGC?AGA?AAA?TTC?TGT??????1896Thr?Asp?Ile?Pro?Ile?Ile?Ile?Gln?Val?Trp?Asn?Ser?Arg?Lys?Phe?Cys

575?????????????????580?????????????????585GAT?CAG?TTC?CTG?GGG?CAG?GTT?ACT?CTC?GAT?GCT?GAC?CCC?AGC?GAC?TGC???????1944Asp?Gln?Phe?Leu?Gly?Gln?Val?Thr?Leu?Asp?Ala?Asp?Pro?Ser?Asp?Cys590?????????????????595?????????????????600?????????????????605CGT?GAT?CTG?AAA?TCT?CTG?TAC?CTG?CGT?AAG?AAG?GGT?GGT?CCT?ACT?GCC???????1992Arg?Asp?Leu?Lys?Ser?Leu?Tyr?Leu?Arg?Lys?Lys?Gly?Gly?Pro?Thr?Ala

610?????????????????615?????????????????620AAA?GTC?AAG?CAA?GGT?CAC?ATC?AGC?TTC?AAA?GTT?ATC?TCT?AGC?GAT?GAT???????2040Lys?Val?Lys?Gln?Gly?His?Ile?Ser?Phe?Lys?Val?Ile?Ser?Ser?Asp?Asp

625?????????????????630?????????????????635CTC?ACT?GAG?CTC?TAAGTAGTCA?TCATCAG????????????????????????????????????2069Leu?Thr?Glu?Leu

640

(2) data of SEQ ID NO:2

(i) sequence signature:

(A) length: 641 amino acid

(B) type: amino acid

(D) topology: linearity

(ii) molecule type: albumen

(xi) sequence description: SEQ ID NO:2Met Gly Pro Pro Leu Lys Leu Phe Lys Asn Gln Lys Tyr Gln Glu Leu 15 10 15Lys Gln Glu Cys Met Lys Asp Gly Arg Leu Phe Cys Asp Pro Thr Phe

20??????????????????25??????????????????30Leu?Pro?Glu?Asn?Asp?Ser?Leu?Phe?Phe?Asn?Arg?Leu?Leu?Pro?Gly?Lys

35??????????????????40??????????????????45Val?Val?Trp?Lys?Arg?Pro?Gln?Asp?Ile?Ser?Asp?Asp?Pro?His?Leu?Ile

50??????????????????55??????????????????60Val?Gly?Asn?Ile?Ser?Asn?His?Gln?Leu?Ile?Gln?Gly?Arg?Leu?Gly?Asn?65??????????????????70??????????????????75??????????????????80Lys?Ala?Met?Ile?Ser?Ala?Phe?Ser?Cys?Leu?Ala?Val?Gln?Glu?Ser?His

85??????????????????90??????????????????95Trp?Thr?Lys?Ala?Ile?Pro?Asn?His?Lys?Asp?Gln?Glu?Trp?Asp?Pro?Arg

100?????????????????105?????????????????110Lys?Pro?Glu?Lys?Tyr?Ala?Gly?Ile?Phe?His?Phe?Arg?Phe?Trp?His?Phe

115?????????????????120?????????????????125Gly?Glu?Trp?Thr?Glu?Val?Val?Ile?Asp?Asp?Leu?Leu?Pro?Thr?Ile?Asn

130?????????????????135?????????????????140Gly?Asp?Leu?Val?Phe?Ser?Phe?Ser?Thr?Ser?Met?Asn?Glu?Phe?Trp?Asn145?????????????????150?????????????????155?????????????????160Ala?Leu?Leu?Glu?Lys?Ala?Tyr?Ala?Lys?Leu?Leu?Gly?Cys?Tyr?Glu?Ala

165?????????????????170?????????????????175Leu?Asp?Gly?Leu?Thr?Ile?Thr?Asp?Ile?Ile?Met?Asp?Phe?Thr?Gly?Thr

180?????????????????185?????????????????190Leu?Ala?Glu?Ile?Ile?Asp?Met?Gln?Lys?Gly?Arg?Tyr?Thr?Asp?Leu?Val

195?????????????????200?????????????????205Glu?Glu?Lys?Tyr?Lys?Leu?Phe?Gly?Glu?Leu?Tyr?Lys?Thr?Phe?Thr?Lys

210?????????????????215?????????????????220Gly?Gly?Leu?Ile?Cys?Cys?Ser?Ile?Glu?Ser?Pro?Ser?Gln?Glu?Glu?Gln225?????????????????230?????????????????235?????????????????240Glu?Val?Glu?Thr?Asp?Trp?Gly?Leu?Leu?Lys?Gly?Tyr?Thr?Tyr?Thr?Met

245?????????????????250?????????????????255Thr?Asp?Ile?Arg?Lys?Leu?Arg?Leu?Gly?Glu?Arg?Leu?Val?Glu?Val?Phe

260?????????????????265?????????????????270Ser?Thr?Glu?Lys?Leu?Tyr?Met?Val?Arg?Leu?Arg?Asn?Pro?Leu?Gly?Arg

275?????????????????280?????????????????285Gln?Glu?Trp?Ser?Gly?Pro?Trp?Ser?Glu?Ile?Ser?Glu?Glu?Trp?Gln?Gln

290?????????????????295?????????????????300Leu?Thr?Val?Thr?Asp?Arg?Lys?Asn?Leu?Gly?Leu?Val?Met?Ser?Asp?Asp305?????????????????310?????????????????315?????????????????320Gly?Glu?Phe?Trp?Met?Ser?Leu?Glu?Asp?Phe?Cys?His?Asn?Phe?His?Lys

325?????????????????330?????????????????335Leu?Asn?Val?Cys?Arg?Asn?Val?Asn?Asn?Pro?Val?Phe?Gly?Arg?Lys?Glu

340?????????????????345?????????????????350Leu?Glu?Ser?Val?Val?Gly?Cys?Trp?Thr?Val?Asp?Asp?Asp?Pro?Leu?Met

355?????????????????360?????????????????365Asn?Arg?Ser?Gly?Gly?Cys?Tyr?Asn?Asn?Arg?Asp?Thr?Phe?Leu?Gln?Asn

370?????????????????375?????????????????380Pro?Gln?Tyr?Ile?Phe?Thr?Val?Pro?Glu?Asp?Gly?His?Lys?Val?Ile?Met385?????????????????390?????????????????395?????????????????400Ser?Leu?Gln?Gln?Lys?Asp?Leu?Arg?Thr?Tyr?Arg?Arg?Met?Gly?Arg?Pro

405?????????????????410?????????????????415Asp?Asn?Tyr?Ile?Ile?Gly?Phe?Glu?Leu?Phe?Lys?Val?Glu?Met?Asn?Arg

420?????????????????425?????????????????430Arg?Phe?Arg?Leu?His?His?Leu?Tyr?Ile?Gln?Glu?Arg?Ala?Gly?Thr?Ser

435?????????????????440?????????????????445Thr?Tyr?Ile?Asp?Thr?Arg?Thr?Val?Phe?Leu?Ser?Lys?Tyr?Leu?Lys?Lys

450?????????????????455?????????????????460Gly?Ser?Tyr?Val?Leu?Val?Pro?Thr?Met?Phe?Gln?His?Gly?Arg?Thr?Ser465?????????????????470?????????????????475?????????????????480Glu?Phe?Leu?Leu?Arg?Ile?Phe?Ser?Glu?Val?Pro?Val?Gln?Leu?Arg?Glu

485??????????????????490?????????????????495Leu?Thr?Leu?Asp?Met?Pro?Lys?Met?Ser?Cys?Trp?Asn?Leu?Ala?Arg?Gly

500?????????????????505?????????????????510Tyr?Pro?Lys?Val?Val?Thr?Gln?Ile?Thr?Val?His?Ser?Ala?Glu?Gly?Leu

515?????????????????520?????????????????525Glu?Lys?Lys?Tyr?Ala?Asn?Glu?Thr?Val?Asn?Pro?Tyr?Leu?Ile?Ile?Lys

530?????????????????535?????????????????540Cys?Gly?Lys?Glu?Glu?Val?Arg?Ser?Pro?Val?Gln?Lys?Asn?Thr?Val?His545?????????????????550?????????????????555?????????????????560Ala?Ile?Phe?Asp?Thr?Gln?Ala?Val?Phe?Tyr?Arg?Arg?Thr?Thr?Asp?Ile

565?????????????????570?????????????????575Pro?Ile?Ile?Ile?Gln?Val?Trp?Asn?Ser?Arg?Lys?Phe?Cys?Asp?Gln?Phe

580?????????????????585?????????????????590Leu?Gly?Gln?Val?Thr?Leu?Asp?Ala?Asp?Pro?Ser?Asp?Cys?Arg?Asp?Leu

595?????????????????600?????????????????605Lys?Ser?Leu?Tyr?Leu?Arg?Lys?Lys?Gly?Gly?Pro?Thr?Ala?Lys?Val?Lys

The data of 610 615 620Gln Gly His Ile Ser Phe Lys Val Ile Ser Ser Asp Asp Leu Thr Glu625 630 635 640Leu (2) SEQ ID NO:3

(i) sequence signature:

(A) length: 1125 base pairs

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ii) molecule type: DNA (genomic)

(iii) hypothetical structure: do not have

(iii (sic)) antisense sequences: do not have

(vi) biogenetic derivation

(A) biology: the mankind

(vii) direct sources:

(B) clone: CAPN6

(ix) feature:

(A) title/keyword: CDS

(B) location: 2..1125

(xi) sequence description: SEQ ID NO:3:G CTT GTT GAG GAG AAG TAC AAG CTA TTC GGA GAA CTG TAC AAA ACA 46 Leu Val Glu Glu Lys Tyr Lys Leu Phe Gly Glu Leu Tyr Lys Thr

1???????????????5??????????????????10??????????????????15TTT?ACC?AAA?GGT?GGT?CTG?ATC?TGC?TGT?TCC?ATT?GAG?TCT?CCC?AAT?CAG?????????94Phe?Thr?Lys?Gly?Gly?Leu?Ile?Cys?Cys?Ser?Ile?Glu?Ser?Pro?Asn?Gln

20??????????????????25??????????????????30GAG?GAG?CAA?GAA?GTT?GAA?ACT?GAT?TGG?GGT?CTG?CTG?AAG?GGC?CAT?ACC????????142Glu?Glu?Gln?Glu?Val?Glu?Thr?Asp?Trp?Gly?Leu?Leu?Lys?Gly?His?Thr

35??????????????????40??????????????????45TAT?ACC?ATG?ACT?GAT?ATT?CGC?AAA?ATT?CGT?CTT?GGA?GAG?AGA?CTT?GTG????????190Tyr?Thr?Met?Thr?Asp?Ile?Arg?Lys?Ile?Arg?Leu?Gly?Glu?Arg?Leu?Val

50??????????????????55??????????????????60GAA?GTC?TTC?AGT?GCT?GAG?AAG?CTG?TAT?ATG?GTT?CGC?CTG?AGA?AAC?CCC????????238Glu?Val?Phe?Ser?Ala?Glu?Lys?Leu?Tyr?Met?Val?Arg?Leu?Arg?Asn?Pro

65??????????????????70??????????????????75TTG?GGA?AGA?CAG?GAA?TGG?AGT?GGC?CCC?TGG?AGT?GAA?ATT?TCT?GAA?GAG???????286Leu?Gly?Arg?Gln?Glu?Trp?Ser?Gly?Pro?Trp?Ser?Glu?Ile?Ser?Glu?Glu?80??????????????????85??????????????????90??????????????????95TGG?CAG?CAA?CTG?ACT?GCA?TCA?GAT?CGC?AAG?AAC?CTG?GGG?CTT?GTT?ATG???????334Trp?Gln?Gln?Leu?Thr?Ala?Ser?Asp?Arg?Lys?Asn?Leu?Gly?Leu?Val?Met

100?????????????????105?????????????????110TCT?GAT?GAT?GGA?GAG?TTT?TGG?ATG?AGC?TTG?GAG?GAC?TTT?TGC?CGC?AAC???????382Ser?Asp?Asp?Gly?Glu?Phe?Trp?Met?Ser?Leu?Glu?Asp?Phe?Cys?Arg?Asn

115?????????????????120?????????????????125TTT?CAC?AAA?CTG?AAT?GTC?TGC?CGC?AAT?GTG?AAC?AAC?CCT?ATT?TTT?GGC???????430Phe?His?Lys?Leu?Asn?Val?Cys?Arg?Asn?Val?Asn?Asn?Pro?Ile?Phe?Gly

130?????????????????135?????????????????140CGA?AAG?GAG?CTG?GAA?TCG?GTG?TTG?GGA?TGC?TGG?ACT?GTG?GAT?GAT?GAT???????478Arg?Lys?Glu?Leu?Glu?Ser?Val?Leu?Gly?Cys?Trp?Thr?Val?Asp?Asp?Asp

145?????????????????150?????????????????155CCC?CTG?ATG?AAC?CGC?TCA?GGA?GGC?TGC?TAT?AAC?AAC?CGT?GAT?ACC?TTC???????526Pro?Leu?Met?Asn?Arg?Ser?Gly?Gly?Cys?Tyr?Asn?Asn?Arg?Asp?Thr?Phe160?????????????????165?????????????????170?????????????????175CTG?CAG?AAT?CCC?CAG?TAC?ATC?TTC?ACT?GTG?CCT?GAG?GAT?GGG?CAC?AAG???????574Leu?Gln?Asn?Pro?Gln?Tyr?Ile?Phe?Thr?Val?Pro?Glu?Asp?Gly?His?Lys

180?????????????????185?????????????????190GTC?ATT?ATG?TCA?CTG?CAG?CAG?AAG?GAC?CTG?CGC?ACT?TAC?CGC?CGA?ATG???????622Val?Ile?Met?Ser?Leu?Gln?Gln?Lys?Asp?Leu?Arg?Thr?Tyr?Arg?Arg?Met

195?????????????????200?????????????????205GGA?AGA?CCT?GAC?AAT?TAC?ATC?ATT?GGC?TTT?GAG?CTC?TTC?AAG?GTG?GAG???????670Gly?Arg?Pro?Asp?Asn?Tyr?Ile?Ile?Gly?Phe?Glu?Leu?Phe?Lys?Val?Glu

210?????????????????215?????????????????220ATG?AAC?CGC?AAA?TTC?CGC?CTC?CAC?CAC?CTC?TAC?ATC?CAG?GAG?CGT?GCT???????718Met?Asn?Arg?Lys?Phe?Arg?Leu?His?His?Leu?Tyr?Ile?Gln?Glu?Arg?Ala

225?????????????????230?????????????????235GGG?ACT?TCC?ACC?TAT?ATT?GAC?ACC?CGC?ACA?GTG?TTT?CTG?AGC?AAG?TAC???????766Gly?Thr?Ser?Thr?Tyr?Ile?Asp?Thr?Arg?Thr?Val?Phe?Leu?Ser?Lys?Tyr240?????????????????245?????????????????250?????????????????255CTG?AAG?AAG?GGC?AAC?TAT?GTG?CTT?GTC?CCA?ACC?ATG?TTC?CAG?CAT?GGT???????814Leu?Lys?Lys?Gly?Asn?Tyr?Val?Leu?Val?Pro?Thr?Met?Phe?Gln?His?Gly

260?????????????????265?????????????????270CGC?ACC?AGC?GAG?TTT?CTC?CTG?AGA?ATC?TTC?TCT?GAA?GTG?CCT?GTC?CAG???????862Arg?Thr?Ser?Glu?Phe?Leu?Leu?Arg?Ile?Phe?Ser?Glu?Val?Pro?Val?Gln

275?????????????????280?????????????????285CTC?AGG?GAA?CTG?ACT?CTG?GAC?ATG?CCC?AAA?ATG?TCC?TGC?TGG?AAC?CTG???????910Leu?Arg?Glu?Leu?Thr?Leu?Asp?Met?Pro?Lys?Met?Ser?Cys?Trp?Asn?Leu

290?????????????????295?????????????????300GCT?CGT?GGC?TAC?CCG?AAA?GTA?GTT?ACT?CAG?ATC?ACT?GTT?CAC?AGT?GCT???????958Ala?Arg?Gly?Tyr?Pro?Lys?Val?Val?Thr?Gln?Ile?Thr?Val?His?Ser?Ala

305?????????????????310?????????????????315GAG?GAC?CTG?GAG?AGG?AGG?TAT?GCC?AAT?GGA?ACT?GTA?AAC?CCA?TAT?TTG??????1006Glu?Asp?Leu?Glu?Arg?Arg?Tyr?Ala?Asn?Gly?Thr?Val?Asn?Pro?Tyr?Leu320?????????????????325?????????????????330?????????????????335GTC?ATC?AAA?TGT?GGA?AAG?GAG?GAA?GTC?CGT?TCT?CCT?GTC?CAG?AAA?AAT??????1054Val?Ile?Lys?Cys?Gly?Lys?Glu?Glu?Val?Arg?Ser?Pro?Val?Gln?Lys?Asn

340?????????????????345?????????????????350ACA?GTT?CAT?GCC?ATT?TTT?GAC?ACC?CAT?GCC?ATT?TTC?TAC?AGA?AGG?ACC??????1102Thr?Val?His?Ala?Ile?Phe?Asp?Thr?His?Ala?Ile?Phe?Tyr?Arg?Arg?Thr

355?????????????????360?????????????????365ACG?GAC?ATT?CCT?ATT?ATA?GTA?CA????????????????????????1125Thr?Asp?Ile?Pro?Ile?Ile?Val

370

(2) data of SEQ ID NO:4

(i) sequence signature:

(A) length: 374 amino acid

(B) type: amino acid

(D) topology: linearity

(ii) molecule type: albumen

(xi) sequence description: SEQ ID NO:4:Leu Val Glu Glu Lys Tyr Lys Leu Phe Gly Glu Leu Tyr Lys Thr Phe 15 10 15Thr Lys Gly Gly Leu Ile Cys Cys Ser Ile Glu Ser Pro Asn Gln Glu

20??????????????????25??????????????????30Glu?Gln?Glu?Val?Glu?Thr?Asp?Trp?Gly?Leu?Leu?Lys?Gly?His?Thr?Tyr

35??????????????????40??????????????????45Thr?Met?Thr?Asp?Ile?Arg?Lys?Ile?Arg?Leu?Gly?Glu?Arg?Leu?Val?Glu

50??????????????????55??????????????????60Val?Phe?Ser?Ala?Glu?Lys?Leu?Tyr?Met?Val?Arg?Leu?Arg?Asn?Pro?Leu?65??????????????????70??????????????????75??????????????????80Gly?Arg?Gln?Glu?Trp?Ser?Gly?Pro?Trp?Ser?Glu?Ile?Ser?Glu?Glu?Trp

85??????????????????90??????????????????95Gln?Gln?Leu?Thr?Ala?Ser?Asp?Arg?Lys?Asn?Leu?Gly?Leu?Val?Met?Ser

100?????????????????105?????????????????110Asp?Asp?Gly?Glu?Phe?Trp?Met?Ser?Leu?Glu?Asp?Phe?Cys?Arg?Asn?Phe

115?????????????????120?????????????????125His?Lys?Leu?Asn?Val?Cys?Arg?Asn?Val?Asn?Asn?Pro?Ile?Phe?Gly?Arg

130?????????????????135?????????????????140Lys?Glu?Leu?Glu?Ser?Val?Leu?Gly?Cys?Trp?Thr?Val?Asp?Asp?Asp?Pro145?????????????????150?????????????????155?????????????????160Leu?Met?Asn?Arg?Ser?Gly?Gly?Cys?Tyr?Asn?Asn?Arg?Asp?Thr?Phe?Leu

165?????????????????170?????????????????175Gln?Asn?Pro?Gln?Tyr?Ile?Phe?Thr?Val?Pro?Glu?Asp?Gly?His?Lys?Val

180?????????????????185?????????????????190Ile?Met?Ser?Leu?Gln?Gln?Lys?Asp?Leu?Arg?Thr?Tyr?Arg?Arg?Met?Gly

195?????????????????200?????????????????205Arg?Pro?Asp?Asn?Tyr?Ile?Ile?Gly?Phe?Glu?Leu?Phe?Lys?Val?Glu?Met

210?????????????????215?????????????????220Asn?Arg?Lys?Phe?Arg?Leu?His?His?Leu?Tyr?Ile?Gln?Glu?Arg?Ala?Gly225?????????????????230?????????????????235?????????????????240Thr?Ser?Thr?Tyr?Ile?Asp?Thr?Arg?Thr?Val?Phe?Leu?Ser?Lys?Tyr?Leu

245?????????????????250?????????????????255Lys?Lys?Gly?Asn?Tyr?Val?Leu?Val?Pro?Thr?Met?Phe?Gln?His?Gly?Arg

260?????????????????265?????????????????270Thr?Ser?Glu?Phe?Leu?Leu?Arg?Ile?Phe?Ser?Glu?Val?Pro?Val?Gln?Leu

275?????????????????280?????????????????285Arg?Glu?Leu?Thr?Leu?Asp?Met?Pro?Lys?Met?Ser?Cys?Trp?Asn?Leu?Ala

290?????????????????295?????????????????300Arg?Gly?Tyr?Pro?Lys?Val?Val?Thr?Gln?Ile?Thr?Val?His?Ser?Ala?Glu305?????????????????310?????????????????315?????????????????320Asp?Leu?Glu?Arg?Arg?Tyr?Ala?Asn?Gly?Thr?Val?Asn?Pro?Tyr?Leu?Val

325?????????????????330?????????????????335Ile?Lys?Cys?Gly?Lys?Glu?Glu?Val?Arg?Ser?Pro?Val?Gln?Lys?Asn?Thr

340?????????????????345?????????????????350Val?His?Ala?Ile?Phe?Asp?Thr?His?Ala?Ile?Phe?Tyr?Arg?Arg?Thr?Thr

355?????????????????360?????????????????365Asp?Ile?Pro?Ile?Ile?Val

370

Claims

1. the CAPN6 calpain gene that has sequence SEQ ID NO.1 or SEQ ID NO.3, its allelic variant, analogue or derivative, they have the homology of 60-100% on the amino acid levels of knowing by inference, and wherein this calpain gene, their allelic variant, analogue or derivative contain following sequence:

(a)Leu-Gly-Asn-Lys-Ala，

Wherein, this sequence is different with the corresponding sequence of people I type calpain, has changed in sequence SEQ ID NO.1 and SEQ ID NO.3 81 Methionin because occupy 115 amino acid cysteine in people I type calpain;

(b)Ala-X-Ser-Cys-Leu-Ala，

Wherein, compare, changed in sequence SEQ ID NO.1 and SEQID NO.3 88 and 91 s' Serine and L-Ala at 122 and 125 s' amino acid alanine and Threonine with the corresponding sequence of people I type calpain;

(c) Gly-Tyr-Thr-(His or Tyr)-Thr-X-Thr,

Wherein, compare with the corresponding sequence of people I type calpain, 272, amino acid Histidine, L-Ala and the Serine in 273 and 275 changed in sequence SEQ ID NO.1 and SEQ ID NO.3 252,253 and 255 tyrosine, Threonine and Threonine, among this external SEQ ID NO.3,274 tyrosine residues has been changed among the SEQID NO.3 254 Histidine in the I type calpain;

(d)Arg-X-Arg-Asn-Pro-Leu-Gly

Wherein, this sequence is different with the corresponding sequence of people I type calpain, because in people I type calpain, occupy the leucine that 298 amino acid tryptophan has changed in sequence SEQ ID NO.1 and SEQ ID NO.3 286, and

X is any natural amino acid in described sequence.

2. one kind by the desired gene construct that comprises CAPN6 calpain gene, its allelic variant or analogue in claim 1, and it is connected to increase genetic expression with one or more conditioning signals are functional.

3. by CAPN6 gene, allelic variant or the analogue amino acid sequence coded of claim 1.

4. the aminoacid sequence of claim 3, it is the protein sequence with enzymic activity.

5. method of differentiating calpain inhibitor, wherein from tissue or cell, separate calpain, its allelic variant or analogue by the sequence encoding of claim 1, and measure by test substances enzyme CAPN6 substrate cracked restraining effect, and at least in other test, to I and/or II type calpain substrate cracked restraining effect, selected the test substances of inhibitory enzyme CAPN6 and at least a other calpains then.

6. the method for claim 5 has wherein been selected inhibitory enzyme CAPN6 not but has been suppressed the test substances of I and/or II type calpain.

7. the method for claim 5 has wherein been selected inhibitory enzyme CAPN6 but has not been suppressed I and/or the test substances of II type calpain.

8. each method among the claim 5-7 has wherein been selected the test substances that can pass cytolemma in cell system.

9. method for preparing enzyme CAPN6 and its allelic variant or analogue, this method comprises is cloned into the gene order of the coding CAPN6 of 1 copy of claim 1, its allelic variant or analogue in a kind of carrier at least, in the host living beings that carrier is fit to, express the gene of codase CAPN6, its allelic variant or analogue then, then from this host living beings, separate described enzyme.

10. the method for claim 9, wherein used carrier may be expressed described gene, its allelic variant or analogue in protokaryon or eukaryotic cell.

11. press the desired method of claim 9 for one kind, wherein be used as bacterium, fungi or the zooblast of host living beings.

12. one kind by the desired method of claim 9, is baculovirus and be insect cell as host living beings as carrier wherein.

13. by among the claim 5-8 each the proteinase inhibitor that can differentiate be used for producing there is the imbalance of calpain dysfunction in medicine with treatment purposes.

14. the calpain inhibitor of claim 13 is used to produce medicine, is selected from the purposes of imbalances such as cardiovascular diseases, immunological disease, inflammation, anaphylactic disease, nervous system disease, neurodegenerative disease or tumour with treatment.

15. the purposes of the aminoacid sequence of claim 3 in the mensuration system.

16. the purposes of the aminoacid sequence of claim 3 aspect production antibody.

17. the gene order of claim 1, its allelic variant or the analogue purposes aspect the production antisense mRNA.

18. the antisense mRNA of claim 17 is being used to produce medicine, has the purposes of the imbalance of calpain dysfunction with treatment.

19. by desired calpain gene in the claim 1 and its allelic variant or analogue in the various imbalances of diagnosis or in the purposes aspect the gene therapy.